New treatments for osteoarthritis using advanced RNA technology
Official title: Carrier Free siRNA Conjugates as Disease Modifying Osteoarthritis Drugs
Funded at Vanderbilt University · NIH-10990891 · Data updated 2026-11-12
This study is looking at a new way to treat osteoarthritis by using special molecules that can block the genes causing the disease, aiming to provide better results than current treatments and help improve joint health instead of just easing pain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | September 10, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $595,117 |
| NIH project number | 1R01AR083410-01A1 |
| Project ID | NIH-10990891 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with osteoarthritis who are seeking more effective treatment options.
✕Less likely to help
Patients with osteoarthritis who are not responsive to genetic therapies or those with other underlying conditions may not benefit from this research.
What this research studies
This research focuses on developing carrier-free siRNA conjugates to treat osteoarthritis, a common degenerative joint disease. By utilizing RNA interference, the study aims to block specific genes that contribute to the progression of osteoarthritis, potentially offering a more effective treatment than current options. The approach involves optimizing these siRNA drugs to target the disease directly at the joint level, which could lead to significant improvements in patient outcomes. The research is innovative as it seeks to create disease-modifying therapies rather than just pain relief.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that modifies the progression of osteoarthritis, improving quality of life for patients.
How similar studies have gone: While RNA interference has shown promise in other areas, this specific application for osteoarthritis is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Duvall, Craig Lewis — Vanderbilt University
- Study coordinator: Duvall, Craig Lewis
Related research
Other NIH-funded projects on the same topics.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Digital biomarkers to guide personalized rehab after ACL injury
Aims to use wearable sensors and phone videos to predict early osteoarthritis risk after ACL surgery so rehabilitation can be tailored to each patient.
-
Aberrant mechano-oxygen coupling linked to zinc-rich mineralization in osteoarthritis
Aims to understand how abnormal joint forces affect cartilage and bone, causing zinc-rich mineral deposits and harmful blood vessel growth in osteoarthritis.
-
Notch signaling in TMJ osteoarthritis: uncovering mechanisms and new targets
Researchers are studying how Notch signaling affects TMJ osteoarthritis to identify new ways to protect and repair the jaw joint.
-
Nanoparticles delivering an sPLA2 blocker for knee osteoarthritis
This project uses tiny, drug-filled nanoparticles to deliver an sPLA2-blocking medicine into the knee to reduce inflammation and slow knee osteoarthritis in people with painful knee OA.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.